MX2019003938A - Compuestos espirociclicos. - Google Patents
Compuestos espirociclicos.Info
- Publication number
- MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A
- Authority
- MX
- Mexico
- Prior art keywords
- spirocyclic compounds
- compounds
- spirocyclic
- ameliorating
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003938A true MX2019003938A (es) | 2019-06-10 |
Family
ID=61831517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003938A MX2019003938A (es) | 2016-10-05 | 2017-10-03 | Compuestos espirociclicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3523306A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6949952B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190075931A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109890827A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017339890A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019005305A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3037064A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265752A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019003938A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019107667A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201817732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018067512A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SMT202000279T1 (it) | 2015-04-03 | 2020-07-08 | Recurium Ip Holdings Llc | Composti spirociclici |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| EP3846904B1 (en) * | 2018-09-07 | 2023-05-31 | Merck Patent GmbH | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2025096858A1 (en) * | 2023-10-31 | 2025-05-08 | C4 Therapeutics, Inc. | Compounds for the degradation of mutant braf |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3305776T (pt) * | 2004-05-14 | 2019-12-17 | Vertex Pharma | Compostos de pirrol como inibidores de proteína quinaseserk e composições farmacêuticas que contêm esses compostos |
| RS51981B (sr) | 2005-12-13 | 2012-02-29 | Schering Corporation | Policiklični derivati indazola koji su inhibitori erk |
| JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
| CA2691417A1 (en) * | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| US20110166124A1 (en) | 2008-07-23 | 2011-07-07 | Mccormick Kevin D | Tricyclic spirocycle derivatives and methods of use |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| ES2609579T3 (es) | 2011-08-29 | 2017-04-21 | VIIV Healthcare UK (No.5) Limited | Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| CA2903431C (en) | 2013-03-14 | 2022-12-06 | Kalyra Pharmaceuticals, Inc. | Bicyclopentane analgesic compounds |
| ES2700200T3 (es) | 2014-12-22 | 2019-02-14 | Lilly Co Eli | Inhibidores de ERK |
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| SMT202000279T1 (it) * | 2015-04-03 | 2020-07-08 | Recurium Ip Holdings Llc | Composti spirociclici |
-
2017
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019005305A2 (pt) | 2019-07-02 |
| US10934304B2 (en) | 2021-03-02 |
| IL265752A (en) | 2019-06-30 |
| US20200207776A1 (en) | 2020-07-02 |
| EP3523306A1 (en) | 2019-08-14 |
| WO2018067512A8 (en) | 2018-11-01 |
| JP2019534261A (ja) | 2019-11-28 |
| US20210115058A1 (en) | 2021-04-22 |
| RU2019107667A3 (cg-RX-API-DMAC7.html) | 2021-01-27 |
| RU2019107667A (ru) | 2020-11-06 |
| CA3037064A1 (en) | 2018-04-12 |
| KR20190075931A (ko) | 2019-07-01 |
| TW201817732A (zh) | 2018-05-16 |
| NZ751398A (en) | 2021-03-26 |
| CN109890827A (zh) | 2019-06-14 |
| EP3523306A4 (en) | 2020-05-06 |
| WO2018067512A1 (en) | 2018-04-12 |
| JP2021193138A (ja) | 2021-12-23 |
| JP6949952B2 (ja) | 2021-10-13 |
| AU2017339890A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003938A (es) | Compuestos espirociclicos. | |
| ZA201807399B (en) | Egfr inhibitor compounds | |
| MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| MX2017001587A (es) | Terapia de combinacion para tratar un paramixovirus. | |
| MX379622B (es) | Compuestos espirociclicos | |
| MX2018003472A (es) | Moduladores de la expresion de kras. | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| PH12018502020A1 (en) | Methods for treating and preventing c. difficile infection | |
| MX2017014436A (es) | Compuestos biciclicos. | |
| MX2021009899A (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
| EP4286005A3 (en) | Cancer treatment | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| WO2016130581A3 (en) | Combination cancer therapy | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer |